Related by context. Frequent words. (Click for all words.) 73 Randomized controlled 61 multicentre 58 multicenter randomized 58 Multicenter 57 prospective randomized controlled 57 Randomized 57 prospective observational 57 placebo controlled clinical 56 Phase Ib clinical 56 nonrandomized 56 prospective multicenter 56 randomized clinical 56 Thrombolysis 55 randomized controlled trial 55 randomized controlled clinical 55 blind randomized controlled 55 Phase III randomized 54 Chronic Heart Failure 54 placebo controlled randomized 54 Acute Myocardial Infarction 53 #mg/day [001] 53 randomized controlled 53 Randomized Controlled Trial 53 Antenatal 53 pharmacokinetics PK 53 randomized 53 Percutaneous Coronary Intervention 53 Radiation Therapy Oncology 53 prospective cohort 53 subanalysis 52 multicenter clinical 52 blinded placebo controlled 52 randomisation 52 thromboprophylaxis 52 blind randomized 51 randomized Phase III 51 ENVISION 51 relapsing multiple sclerosis 51 multicenter randomized double 51 multicenter 51 paclitaxel eluting stents 51 retrospective cohort study 51 phase IIa 51 double blinded placebo 50 Phase 1b clinical 50 prospective randomized 50 PREZISTA r 50 randomized #:# 49 prospectively defined 49 RRMS patients 49 secondary efficacy endpoints 49 label multicenter 49 randomized placebo controlled 49 Randomization 49 Pharmacokinetic 49 Cloretazine R VNP#M 49 SWOG 49 phase IIb clinical 49 analgesic efficacy 48 randomized double 48 antibiotic prophylaxis 48 generalized anxiety disorder GAD 48 PRECiSE 48 generalizability 48 patients undergoing percutaneous 48 PRECISE 48 blind randomized placebo 48 substudy 48 Secondary endpoints include 48 Adalimumab 48 SYNTAX 48 phase IIb 48 noninferiority 48 placebo controlled studies 48 TRITON TIMI 48 neoadjuvant 48 Carotid 48 neuroleptics 48 Solid Tumors 48 Secondary endpoints 47 Efficacy 47 efficacy tolerability 47 anticoagulation therapy 47 nab paclitaxel 47 active comparator 47 KRN# 47 dabigatran etexilate 47 randomly assigned 47 primary hypercholesterolemia 47 univariate 47 Pivotal Phase III 47 Phase 1a 47 acute coronary syndromes ACS 47 safety tolerability pharmacokinetics 47 pharmacokinetic PK 47 Phase Ia 47 ATTRACT 47 ascending doses 47 Co Principal Investigator 46 placebo controlled Phase 46 multicenter study